Safety concerns about digoxin after acute myocardial infarction.
We examined clinical outcomes associated with non-randomised digoxin therapy in a postmyocardial infarction population with clinical heart failure (AIRE study). Our results raise concern about the safety of digoxin in this population.
Spargias
K S
KS
Hall
A S
AS
Ball
S G
SG
D000328:Adult; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004077:Digoxin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D011358:Product Surveillance, Postmarketing; D017180:Tachycardia, Ventricular / Q000139:chemically induced / Q000401:mortality; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D004077:Digoxin